Recruiting

Observational Study

Sponsor:

Laval University

Code:

NCT02282436

Conditions

Chronic Obstructive Pulmonary Disease

Eligibility Criteria

Sex: All

Age: 50 - 70+

Healthy Volunteers: Accepted

Interventions

No specific intervention for this study

Study Details

Brief summary:

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Its prevalence is in progression and COPD is expected to become the fourth leading cause of death by 2030. COPD is characterized by periods of stability interspersed with acute infectious/inflammatory flare-ups, also called acute exacerbations, during which patients deteriorate, sometimes to the point of requiring immediate medical assistance. Although most patients eventually recover, repeated episodes of exacerbations may accelerate COPD progression. Exacerbations may further compromise the integrity of limb muscles by promoting further loss in muscle mass and strength.

The overall objective of this substudy is to elucidate how an acute COPD exacerbation may affect limb muscles.

Conditions

Chronic Obstructive Pulmonary Disease

Study ID

NCT02282436

Start date

May, 2012

Status verified date

Sep, 2016

Completion date

May, 2018

Anticipated

Primary completion date

May, 2017

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 50 - 70+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • male and female
  • COPD with an FEV1 of under 60% of predicted
  • non-smoker
  • between 50 and 75 years old
  • experiencing an acute exacerbation of COPD (24-48 hours, before treatment)

Exclusion Criteria:

  • all inflammatory disease (HIV, cancer, renal and cardiac deficiency)
  • hormonal dysregulation
  • inferior limb pathology
  • neuromuscular pathology
  • history of tobacco or alcool abuse
  • oxygen dependent

Study Design

Enrollment

20 participants

Anticipated

Interventions and Outcome Measures

Arms

COPD exacerbation

No specific intervention for this study

Interventions

No specific intervention for this study

No specific intervention for this study

Primary outcome measure

  • Increased levels of ubiquitin proteasome pathway proteins in patients experiencing an acute exacerbation of COPD [ Time Frame: during an acute exacerbation of COPD (first 24-48 hours, before treatment) ]

Central Contacts and Locations

Central contacts

Locations

Centre de recherche de l'Institut de cardiologie et de pneumologie de Québec

Recruiting

Québec, Quebec, Canada, G1V 4G5

Contacts

More Information

Sponsor

Laval University

Last update posted

Sep 8, 2016

Last verified

Sep, 2016

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Laval University on 2016-09-08.